Celldex Therapeutics, Inc. (NASDAQ:CLDX), announced that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago. Celldex Therapeutics, Inc. (NASDAQ:CLDX), weekly performance is 13.61%. On last trading day company shares ended up $24.43. Analysts mean target price for the company is $36.00. Celldex Therapeutics, Inc. (NASDAQ:CLDX), distance from 50-day simple moving average (SMA50) is -12.11%.
On May 09, 2014, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2014 Health Care Conference being held at The Encore at Wynn in Las Vegas, Nevada. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), advanced 2.01% in last trading session and ended the day on $7.62. SPPI, Gross Margin is 81.70% and its return on assets is -14.30%. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), quarterly performance is -5.81%.
On May 12, 2014, Neuralstem, Inc. (NYSEMKT:CUR), reported its financial results for the three months ended March 31, 2014 and provided a business and clinical update. The net loss in the first quarter of 2014 also included other expenses comprised of approximately $432,000 in interest expense related to our long term debt and a $334,000 non-cash expense related to the change in the fair value of the our derivative instruments. The first quarter of 2013 included a $667,000 non-cash expense related to the modification of certain stock purchase warrants. Neuralstem, Inc. (NYSEMKT:CUR), shares moved up 9.84% in last trading session and was closed at $3.46, while trading in range of $3.11 – 3.65. Neuralstem, Inc. (NYSEMKT:CUR), year to date (YTD) performance is 18.90%.
On May 13, 2014, CEL-SCI Corporation (NYSEMKT:CVM), reported financial results for the quarter ended March 31, 2014. CEL-SCI reported an operating loss of ($6,226,435) for the quarter ended March 31, 2014 versus an operating loss of ($4,239,824) for the quarter ended March 31, 2013. The operating loss for the six months ended March 31, 2014 was ($12,160,745) versus ($9,283,337) during the six months ended March 31, 2013. CEL-SCI Corporation (NYSEMKT:CVM), ended the last trading day at $1.16. Company weekly volatility is calculated as 9.39% and price to cash ratio as 5.76. CEL-SCI Corporation (NYSEMKT:CVM), showed a negative weekly performance of 2.52%.
On May 09, 2014, Synthetic Biologics Inc (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its Clostridium difficile (C. diff) program. The company’s extensive C. diff patent estate now includes over 25 United States and international patents. Synthetic Biologics Inc (NYSEMKT:SYN), weekly performance is -14.71%. On last trading day company shares ended up $1.16. Analysts mean target price for the company is $3.95. Synthetic Biologics Inc (NYSEMKT:SYN), distance from 50-day simple moving average (SMA50) is -53.07%.